The editors have asked me to write this foreword probably for two reasons: First, I have spent 35 years trying to develop radiolabeled compounds that would help diagnose and treat disease. I, and the people from my laboratory, have been much involved with developing Nan'I for the diagnosis and treatment of hyperthyroidism and well-differentiated thyroid cancer. Second, I was a participant throughout the entire symposium upon which this book is based. Our latest '311-labeled compound, [l3lll metaiodobenzylguanidine, took us 13 years to develop. It has succeeded in diagnosing and treating…mehr
The editors have asked me to write this foreword probably for two reasons: First, I have spent 35 years trying to develop radiolabeled compounds that would help diagnose and treat disease. I, and the people from my laboratory, have been much involved with developing Nan'I for the diagnosis and treatment of hyperthyroidism and well-differentiated thyroid cancer. Second, I was a participant throughout the entire symposium upon which this book is based. Our latest '311-labeled compound, [l3lll metaiodobenzylguanidine, took us 13 years to develop. It has succeeded in diagnosing and treating adrenergic tumors '31 under circumstances where Na 1 would have failed for the diagnosis and treatment of thyroid cancer. I therefore hope that more scientists will be attracted to this field. This book is written by intelligent, experienced investigators who are knowl edgeable. It is a must for anyone new in the field. For the experienced, I would like to remind you that I attended the entire symposium; the breadth and timeliness of the update has helped us to redirect some of our current efforts into more scientifically productive channels. William H. Beierwaltes, M.D.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Die Herstellerinformationen sind derzeit nicht verfügbar.
Inhaltsangabe
1 Animal Models in Biomedical Research and Radiotracer Design.- Brief Survey of Chapters.- Guidelines for Research with Animals.- References.- 2 The Development of Radiotracers that are Substrates FOR (Catecholamine) Uptake1 and Uptake2.- Introduction: Development of Informational Drugs.- Catecholamine Uptake1 and Uptake2.- Compounds Other Than Catecholamines that Participate in Uptake1 and Uptake2.- Species Differences.- The Special Case of the Adrenal Medulla.- Other Extraneuronal Uptake.- Possible Pathological Role of Changes in Uptake1.- Possible Future Directions of Research.- Summary.- References.- 3 Monoclonal Antibodies: the Design of Appropriate Carrier and Evaluation Systems.- Monoclonal Antibody Applications.- Requirements for the Receptor Antigen.- Requirements for the Carrier Antibody.- Tumor Model Systems.- Summary.- References.- 4 Small Animal Oncological Models for Screening Diagnostic Radiotracers.- The Need for Animal Tumor Models.- Cancer.- Classification of Neoplasms.- Growth and Spread of Neoplasms.- Animal Tumor Models.- Selection of Animal Tumor Models Based on Mechanism of Uptake of the Radiotracer.- Animal Tumor Models in the Literature of Radiotracers and Radiopharmaceuticals.- References.- 5 111In-Labeled Platelets for the Detection of Vascular Disorders in Animal Models.- Acute Arterial Lesion Model.- Atherosclerosis.- Coronary Artery Thrombosis.- Vascular Grafts.- References.- 6 Animal Models in the Study of Hepatobiliary Radiotracers.- and Characteristics of Hepatobiliary Agents.- Species and Hepatobiliary Excretion.- Laboratory Animal Technique Considerations.- Summary.- References.- 7 Experimental Models and Evaluation of Animal Data for Renal Radiodiagnostic Agents.- Evaluation of Animal Biodistribution Data.- Comparison of Biodistribution of Renal Agents in Different Species.- Choice of Animal Models.- Models of Human Renal Diseases in the Rat.- Conclusions.- References.
1 Animal Models in Biomedical Research and Radiotracer Design.- Brief Survey of Chapters.- Guidelines for Research with Animals.- References.- 2 The Development of Radiotracers that are Substrates FOR (Catecholamine) Uptake1 and Uptake2.- Introduction: Development of Informational Drugs.- Catecholamine Uptake1 and Uptake2.- Compounds Other Than Catecholamines that Participate in Uptake1 and Uptake2.- Species Differences.- The Special Case of the Adrenal Medulla.- Other Extraneuronal Uptake.- Possible Pathological Role of Changes in Uptake1.- Possible Future Directions of Research.- Summary.- References.- 3 Monoclonal Antibodies: the Design of Appropriate Carrier and Evaluation Systems.- Monoclonal Antibody Applications.- Requirements for the Receptor Antigen.- Requirements for the Carrier Antibody.- Tumor Model Systems.- Summary.- References.- 4 Small Animal Oncological Models for Screening Diagnostic Radiotracers.- The Need for Animal Tumor Models.- Cancer.- Classification of Neoplasms.- Growth and Spread of Neoplasms.- Animal Tumor Models.- Selection of Animal Tumor Models Based on Mechanism of Uptake of the Radiotracer.- Animal Tumor Models in the Literature of Radiotracers and Radiopharmaceuticals.- References.- 5 111In-Labeled Platelets for the Detection of Vascular Disorders in Animal Models.- Acute Arterial Lesion Model.- Atherosclerosis.- Coronary Artery Thrombosis.- Vascular Grafts.- References.- 6 Animal Models in the Study of Hepatobiliary Radiotracers.- and Characteristics of Hepatobiliary Agents.- Species and Hepatobiliary Excretion.- Laboratory Animal Technique Considerations.- Summary.- References.- 7 Experimental Models and Evaluation of Animal Data for Renal Radiodiagnostic Agents.- Evaluation of Animal Biodistribution Data.- Comparison of Biodistribution of Renal Agents in Different Species.- Choice of Animal Models.- Models of Human Renal Diseases in the Rat.- Conclusions.- References.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826